Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Grant of Options


RNS Number : 2118A
Evgen Pharma PLC
22 December 2017
 

For immediate release                                                                                                                 22 December 2017

 

 

 

 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 21 December 2017, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 807,234 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

PDMR

Position

Options granted

Dr Stephen Franklin

Chief Executive Officer

          437,760

 

Richard Moulson

Chief Financial Officer

  289,352

 

David Chadwick

Head of Clinical Operations

69,444

 

The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 24 November 2017.

These nil cost options are subject to the rules of the LTIP and will vest based on share price performance between the date of grant and the third anniversary of grant.

 

Enquiries:

Evgen Pharma plc

c/o +44 (0) 20 7466 5000

Dr Stephen Franklin, CEO

Richard Moulson, CFO


www.evgen.com




Northland Capital Partners Limited

+44 (0) 20 3861 6625

Matthew Johnson, Gerry Beaney (Corporate Finance)


John Howes, Rob Rees (Corporate Broking)




Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson




Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Steve Franklin

2

Reason for the notification

a)

Position/status

Chief Executive

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

437,760


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

21 December 2017

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

289,352


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

21 December 2017

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

David Chadwick

2

Reason for the notification

a)

Position/status

Head of Clinical Operations

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

  69,444


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

21 December 2017

g)

Place of the transaction

London Stock Exchange, AIM

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKBDKKBDDABB

Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use